Crossmark

New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024

Crossref DOI link: https://doi.org/10.1038/s41401-024-01466-7

Published Online: 2025-01-27

Published Print: 2025-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wong, Shu Wei

Yang, Yong-yu

Chen, Hui

Xie, Li

Shen, Xi-zhong

Zhang, Ning-ping https://orcid.org/0000-0003-1262-4331
Wu, Jian https://orcid.org/0000-0001-9933-7364
License Information

Text and Data Mining valid from 2025-01-27

Version of Record valid from 2025-01-27
More Information

Article History

Received: 14 September 2024

Accepted: 18 December 2024

First Online: 27 January 2025

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below